Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trazodone SCHEMBL28167 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL28226073 | 0.99 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL29575935 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL3402550 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL61754 | 0.99 | KDM4E (1.00) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL120883 | 0.98 | HTR1A (0.96) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL11089944 | 0.98 | HTR1A (0.98) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL27570399 | 0.95 | DRD2 (0.90) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL8741340 | 0.94 | DRD2 (0.89) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| Trazodone SCHEMBL23145121 | 0.93 | HTR1A (0.87) | HTR1ADRD2HTR2AKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119863255-A | Time-interval composite operation method and system for independent energy storage power station based on target optimization | 国网辽宁省电力有限公司经济技术研究院 | 2025-04-22 | — | — | CN | claimed |
| US-12241889-B2 | Malate to detect and as a target for fibromyalgia | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| CN-119431364-A | Preparation method of trazodone hydrochloride | 重庆锐恩医药有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| US-20220065846-A1 | MALATE TO DETECT AND AS A TARGET FOR FIBROMYALGIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-03-03 | — | — | US | claimed |
| WO-2025108998-A1 | SYSTEM AND METHOD FOR TREATING URBAN AND/OR INDUSTRIAL EFFLUENT | OZOVAL (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025108992-A1 | SYSTEM AND METHOD FOR ELECTRO-OZONATION OF AN EFFLUENT | RHOUMA MOHAMED (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025108999-A1 | SYSTEM AND METHOD FOR TREATING EFFLUENT FROM A VEHICLE WASHING STATION | OZOVAL (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025108997-A1 | SYSTEM AND METHOD FOR HYBRID OZONATION OF AN EFFLUENT | RHOUMA MOHAMED (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025109001-A1 | SYSTEM AND METHOD FOR TREATING EFFLUENT FROM AN OIL PLATFORM | OZOVAL (FR) | 2025-05-30 | — | — | WO | disclosed |
| CN-120051660-A | Air purifier for refrigerator | 法布里奇实验室有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115304595-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11490856-B2 | Method and a system for analyzing neuropharmacology of a drug | CITY UNIVERSITY OF HONG KONG (HK) | 2022-11-08 | — | — | US | disclosed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220065846-A1 | MALATE TO DETECT AND AS A TARGET FOR FIBROMYALGIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-03-03 | — | — | US | disclosed |
| EP-3949973-A2 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | Gentelon, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | HTR2A 99/4885SLC6A4 79/4885HTR2C 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.